Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 41Carcinoma, Non-Small-Cell Lung 31Triple Negative Breast Neoplasms 23Nasopharyngeal Carcinoma 23Stomach Neoplasms 22Esophageal Neoplasms 20Esophageal Squamous Cell Carcinoma 19Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 14Uterine Cervical Neoplasms 12Colorectal Neoplasms 12Sarcoma 10Pancreatic Neoplasms 9Lung Neoplasms 9Recurrence 7Neoplasm Metastasis 7Melanoma 6Liver Neoplasms 6Hodgkin Disease 6Cholangiocarcinoma 6Biliary Tract Neoplasms 5Advanced Gastric Cancer 5Small Cell Lung Carcinoma 4Osteosarcoma 4Neoplasms 4Locally Advanced Gastric Cancer 4Advanced Solid Tumor 4Solid Tumor 3Respiratory Tract Diseases 3Rectal Neoplasms 3

Interventions

Pemetrexed 8Carboplatin 6Cisplatin 4Bevacizumab 4pembrolizumab 3anlotinib 3Platinum 2Paclitaxel 2tusamitamab ravtansine 1ixabepilone 1icotinib 1endostar protein 1camrelizumab 1Gefitinib 1Erlotinib Hydrochloride 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-squamous Non-small Cell Lung Cancer × camrelizumab × Clear all
NCT06335355 2024-03-28

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Shanghai Shengdi Pharmaceutical Co., Ltd

Phase 2/3 Not yet recruiting
401 enrolled
Thoracic

Non-squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡